^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

    Excerpt:
    ...Documented HER2 or EGFR exon 18 mutation...
    Trial ID:
    SUMMIT
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer

    Published date:
    11/17/2020
    Excerpt:
    The combination of N+T+F demonstrated encouraging clinical activity in heavily pre-treated HER2-mutant, HR+, HER2-non-amplified MBC, including patients who had previously received either fulvestrant and/or CDK4/6 inhibitor-based therapies...
    Secondary therapy:
    fulvestrant
    Trial ID:
    SUMMIT